The delisting is now final with no further appeal options. Expect continued low liquidity and potential further price erosion as remaining Nasdaq-market holders are forced to sell. Monitor for any reverse stock split or other compliance efforts, but near-term recovery appears unlikely.
RVPH drugs
RVPH drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 10 $0.6200entry
- T+1 · 4mo ago −3.23%α −2.46% · $0.6000
- T+5 · 4mo ago −8.87%α −7.33% · $0.5650
- T+20 · 3mo ago −22.98%α −25.40% · $0.4775
- T+60 · 6w ago −19.35%α −22.24% · $0.5000
Price Chart
How similar events traded
Executive Summary
Nasdaq has filed a Form 25-NSE to remove Reviva Pharmaceuticals Holdings, Inc. from listing and registration, effective July 20, 2026, following the company's failure to maintain compliance with the minimum bid price rule (Listing Rule 5550(a)(2)). The delisting was finalized on June 26, 2026, after an unsuccessful appeal process. This confirms the loss of exchange listing, severely reducing liquidity and institutional access for RVPH shares.
Key Facts
- Delisting effective at the opening of trading on July 20, 2026.
- Company failed to meet Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 bid price).
- Final delisting determination made on June 26, 2026.
- Stock has been suspended from Nasdaq since May 14, 2026, and now trades on OTC markets.
- Prior appeal and extension requests were denied; the company could not achieve compliance.
Financial Impact
Loss of Nasdaq listing eliminates exchange-traded liquidity and likely restricts institutional ownership, further pressuring the stock price on OTC markets.
Risk Factors
- Further price decline due to forced selling by institutional holders unable to hold OTC stocks.
- Potential loss of analyst coverage and reduced visibility for the company's pipeline.
- Risk of eventual deregistration if the company fails to meet OTC reporting requirements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 25-NSE Filing (Primary) | 0001354457-26-000658 |
| Document: 0001354457-26-000658-index.html | 0001354457-26-000658 |
| Document: 0001354457-26-000658.txt | 0001354457-26-000658 |
Track record
12 reports on RVPH
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +15.66% at T+60 after the Mar 18, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 No price data
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.3533 Now $0.3504 −0.81% settles Feb 11
- Nov 9, 20267d ago DEF 14A Neutral 4/10 Entry $0.3521 Now $0.3504 −0.47% settles Feb 8
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $0.3521 to $0.3521 Now $0.3504 −0.47% · 0.00% +5.48% vs SPY
- Jul 10, 202618w ago 25-NSE Bearish 7/10 Viewing Entry $0.6200 to $0.5000 Now $0.3504 +43.48% ▲ +19.35% +22.24% vs SPY
- May 13, 202626w ago Press Release Bearish 7/10 Entry $0.3900 to $0.4303 Now $0.3504 +10.14% ▼ −10.33% −6.74% vs SPY
- May 13, 202626w ago 8-K Bearish 8/10 Entry $0.3521 to $0.4775 Now $0.3504 +0.47% ▼ −35.62% −31.19% vs SPY
- Apr 15, 202630w ago 8-K Neutral 5/10 Entry $0.8900 to $0.5731 Now $0.3504 −60.62% ▼ −35.61% −43.74% vs SPY
- Mar 30, 202633w ago Press Release Mixed 6/10 Entry $0.6600 to $0.6000 Now $0.3504 −46.90% ▼ −9.09% −25.58% vs SPY
- Mar 18, 202634w ago Press Release Bearish 6/10 Entry $0.8300 to $0.7000 Now $0.3504 +57.78% ▲ +15.66% +30.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers